Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs TransMedics Group Inc (TMDX) Price & Performance

Dow Jones Industrial Average ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs TransMedics Group Inc — how do they compare? Dow Jones Industrial Average ETF trades at $524.94, while TransMedics Group Inc trades at $75.64 (market cap $2.58B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

DIATMDX
52-Week High
$530.02$150.42
52-Week Low
$435.72$61.99
Market Cap
$2.58B
Sector
Technology
Enterprise Value
$2.98B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average's 30 blue-chip stocks, providing diversified exposure to large-cap U.S. equities. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting its tech weighting. Dividend distributions continue with scheduled payouts through mid-2026.

Outlook remains positive given the Dow's 8% year-to-date gain and DIA's 10-year average annual return of 13.3%. Key opportunities include broad market exposure and dividend income, while risks involve Fed policy shifts and concentration in cyclical sectors. Analyst sentiment is favorable due to the ETF's low-cost structure and historical performance.

TransMedics Group Inc

TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.

The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.

Returns comparison

Trailing returns across standard periods

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX